Distinct from high-grade serous ovarian carcinoma (HGSOC), MOC is characterized by frequent Kirsten rat sarcoma viral oncogene homolog (KRAS) gene mutations and human epidermal growth factor receptor 2 (HER2) amplification—and lacks the widespread genomic instability and TP53 mutations typical of HGSOC [5,6,7,8]. This evidence concerns the gene ERBB2 and ovarian serous carcinoma.